Moshe Talpaz

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Anatomy

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
O'Brien Susan; Berman Ellin; Borghaei Hossein; Deangelo Daniel J; Devetten Marcel P; Devine Steven; Erba Harry P; Gotlib Jason; Jagasia Madan; Moore Joseph O; Mughal Tariq; Pinilla-Ibarz Javier; Radich Jerald P; Shah Md Neil P; Shami Paul J; Smith B Douglas; Snyder David S; Tallman Martin S; Talpaz Moshe; Wetzler Meir
NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia.
Jakubowiak Andrzej J; Kendall Tara; Al-Zoubi Ammar; Khaled Yasser; Mineishi Shin; Ahmed Asra; Campagnaro Erica; Brozo Christine; Braun Thomas; Talpaz Moshe; Kaminski Mark S
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Dlugosz Andrzej A; Talpaz Moshe
Following the hedgehog to new cancer therapies.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Moshe Talpaz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: O'Brien Susan; Berman Ellin; Borghaei Hossein; Deangelo Daniel J; Devetten Marcel P; Devine Steven; Erba Harry P; Gotlib Jason; Jagasia Madan; Moore Joseph O; Mughal Tariq; Pinilla-Ibarz Javier; Radich Jerald P; Shah Md Neil P; Shami Paul J; Smith B Douglas; Snyder David S; Tallman Martin S; Talpaz Moshe; Wetzler Meir
NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):984-1023.
2009: Jakubowiak Andrzej J; Kendall Tara; Al-Zoubi Ammar; Khaled Yasser; Mineishi Shin; Ahmed Asra; Campagnaro Erica; Brozo Christine; Braun Thomas; Talpaz Moshe; Kaminski Mark S
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5015-22.
2009: Dlugosz Andrzej A; Talpaz Moshe
Following the hedgehog to new cancer therapies.
The New England journal of medicine 2009;361(12):1202-5.
2009: Dorr David A; Burdon Rachel; West Dennis P; Lagman Jennifer; Georgopoulos Christina; Belknap Steven M; McKoy June M; Djulbegovic Benjamin; Edwards Beatrice J; Weitzman Sigmund A; Boyle Simone; Tallman Martin S; Talpaz Moshe; Sartor Oliver; Bennett Charles L
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3850-5.
2008: Wu Ji; Meng Feng; Kong Ling-Yuan; Peng Zhenghong; Ying Yunming; Bornmann William G; Darnay Bryant G; Lamothe Betty; Sun Hanshi; Talpaz Moshe; Donato Nicholas J
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Journal of the National Cancer Institute 2008;100(13):926-39.
2008: Savona Michael; Talpaz Moshe
Getting to the stem of chronic myeloid leukaemia.
Nature reviews. Cancer 2008;8(5):341-50.
2008: Quintás-Cardama A; Gibbons D L; Kantarjian H; Talpaz M; Donato N; Cortes J
Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):885-8.
2008: Wu Ji; Meng Feng; Lu Henry; Kong Ling; Bornmann William; Peng Zhenghong; Talpaz Moshe; Donato Nicholas J
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Blood 2008;111(7):3821-9.
2008: Bixby Dale L; Talpaz Moshe
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Clinical lymphoma & myeloma 2008;8 Suppl 3():S95-S106.
2008: Talpaz Moshe
The fine tuning of therapy for chronic myeloid leukemia and upcoming challenges.
Clinical lymphoma & myeloma 2008;8 Suppl 3():S74.
2008: Saddler Chris; Ouillette Peter; Kujawski Lisa; Shangary Sanjeev; Talpaz Moshe; Kaminski Mark; Erba Harry; Shedden Kerby; Wang Shaomeng; Malek Sami N
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Blood 2008;111(3):1584-93.
2008: Hochhaus Andreas; Druker Brian; Sawyers Charles; Guilhot Francois; Schiffer Charles A; Cortes Jorge; Niederwieser Dietger W; Gambacorti-Passerini Carlo; Stone Richard M; Goldman John; Fischer Thomas; O'Brien Stephen G; Reiffers Jose J; Mone Manisha; Krahnke Tillmann; Talpaz Moshe; Kantarjian Hagop M
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Blood 2008;111(3):1039-43.
2007: Kujawski Lisa; Talpaz Moshe
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Leukemia & lymphoma 2007;48(12):2310-22.
2007: Kujawski Lisa A; Talpaz Moshe
The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Cytokine & growth factor reviews 2007;18(5-6):459-71.
2007: O'Brien Susan; Berman Ellin; Bhalla Kapil; Copelan Edward A; Devetten Marcel P; Emanuel Peter D; Erba Harry P; Greenberg Peter L; Moore Joseph O; Przepiorka Donna; Radich Jerald P; Schilder Russell J; Shami Paul; Smith B Douglas; Snyder David S; Soiffer Robert J; Tallman Martin S; Talpaz Moshe; Wetzler Meir;
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(5):474-96.
2007: Guilhot Francois; Apperley Jane; Kim Dong-Wook; Bullorsky Eduardo O; Baccarani Michele; Roboz Gail J; Amadori Sergio; de Souza Carmino A; Lipton Jeffrey H; Hochhaus Andreas; Heim Dominik; Larson Richard A; Branford Susan; Muller Martin C; Agarwal Prasheen; Gollerkeri Ashwin; Talpaz Moshe
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Blood 2007;109(10):4143-50.
2007: Bartholomeusz Geoffrey; Talpaz Moshe; Bornmann William; Kong Ling-Yuan; Donato Nicholas J
Degrasyn activates proteasomal-dependent degradation of c-Myc.
Cancer research 2007;67(8):3912-8.
2007: Kantarjian Hagop; O'Brien Susan; Talpaz Moshe; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Rios Mary Beth; Shan Jianqin; Giles Francis; Cortes Jorge
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Bartholomeusz Geoffrey A; Talpaz Moshe; Kapuria Vaibhav; Kong Ling Yuan; Wang Shimei; Estrov Zeev; Priebe Waldemar; Wu Ji; Donato Nicholas J
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Blood 2007;109(8):3470-8.
2007: Quintas-Cardama Alfonso; Kantarjian Hagop; Jones Dan; Nicaise Claude; O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Blood 2007;109(2):497-9.
2006: Kantarjian Hagop M; Talpaz Moshe; Giles Francis; O'Brien Susan; Cortes Jorge
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Polek Tara C; Talpaz Moshe; Spivak-Kroizman Taly R
TRAIL-induced cleavage and inactivation of SPAK sensitizes cells to apoptosis.
Biochemical and biophysical research communications 2006;349(3):1016-24.
2006: Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios M B; Verstovsek S; Cortes J
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(10):1767-73.
2006: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Jones Daniel; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Ravandi Farhad; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Kurzrock Razelle; Talpaz Moshe; Li Lan; Estrov Zeev
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Leukemia & lymphoma 2006;47(8):1651-64.
2006: Savona Michael; Talpaz Moshe
Chronic myeloid leukemia: changing the treatment paradigms.
Oncology (Williston Park, N.Y.) 2006;20(7):707-11; discussion 712-4, 719, 724.
2006: Talpaz Moshe; Shah Neil P; Kantarjian Hagop; Donato Nicholas; Nicoll John; Paquette Ron; Cortes Jorge; O'Brien Susan; Nicaise Claude; Bleickardt Eric; Blackwood-Chirchir M Anne; Iyer Vishwanath; Chen Tai-Tsang; Huang Fei; Decillis Arthur P; Sawyers Charles L
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
2006: Polek Tara C; Talpaz Moshe; Spivak-Kroizman Taly
The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation.
Biochemical and biophysical research communications 2006;343(1):125-34.
2006: Cortes Jorge E; Talpaz Moshe; O'Brien Susan; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Rios Mary B; Shan Jenny; Kantarjian Hagop M
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Ault Patricia; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Beran Miloslav; Rios Mary Beth; Koller Charles; Giles Francis; Keating Michael; Talpaz Moshe; Cortes Jorge
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Chandra Joya; Tracy Jeannette; Loegering David; Flatten Karen; Verstovsek Srdan; Beran Miloslav; Gorre Mercedes; Estrov Zeev; Donato Nicholas; Talpaz Moshe; Sawyers Charles; Bhalla Kapil; Karp Judith; Sausville Edward; Kaufmann Scott H
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
2006: Borthakur Gautam; Kantarjian Hagop; Daley George; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; Sugrue Mary; Cortes Jorge
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2005: O'Brien Susan; Berman Ellin; Bhalla Kapil; Copelan Edward A; Devetten Marcel P; Emanuel Peter D; Erba Harry P; Greenberg Peter L; Moore Joseph O; Przepiorka Donna; Radich Jerald P; Schilder Russell J; Shami Paul; Smith B Douglas; Snyder David S; Soiffer Robert J; Tallman Martin S; Talpaz Moshe; Wetzler Meir
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(6):732-55.
2005: Gao H; Lee B-N; Talpaz M; Donato N J; Cortes J E; Kantarjian H M; Reuben J M
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(11):1905-11.
2005: Johnson Faye M; Saigal Babita; Talpaz Moshe; Donato Nicholas J
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6924-32.
2005: Talpaz Moshe; Rakhit Ashok; Rittweger Karen; O'Brien Susan; Cortes Jorge; Fettner Scott; Hooftman Leon; Kantarjian Hagop
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6247-55.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Wierda William; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Shan Jianqin; Cortes Jorge
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Amit-Vazina M; Shishodia S; Harris D; Van Q; Wang M; Weber D; Alexanian R; Talpaz M; Aggarwal B B; Estrov Z
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.
British journal of cancer 2005;93(1):70-80.
2005: Issa Jean-Pierre J; Gharibyan Vazganush; Cortes Jorge; Jelinek Jaroslav; Morris Gail; Verstovsek Srdan; Talpaz Moshe; Garcia-Manero Guillermo; Kantarjian Hagop M
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3948-56.
2005: Saba Rashid; Jabbour Elias; Giles Francis; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Freireich Emil J; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Jones Dan; Luthra Rajyalakshmi; Shan Jenny; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Rios Mary B; Kantarjian Hagop
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Shan Jianqin; Rios Mary Beth; Champlin Richard; de Lima Marcos; Cortes Jorge
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Gale Robert Peter; Horowitz Mary M; Talpaz Moshe; Scheinberg David A; Molldrem Jeffrey; Li Zihai; Baccarani Michele; Goldman John M; Tura Sante
Immune therapy of chronic myelogenous leukemia.
Leukemia research 2005;29(5):583-6.
2005: Tefferi Ayalew; Dewald Gordon W; Litzow Mark L; Cortes Jorge; Mauro Michael J; Talpaz Moshe; Kantarjian Hagop M
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(3):390-402.
2005: Quintas-Cardama Alfonso; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Rios Mary Beth; Hayes Kimberly; Glassman Armand; Bekele B Nebiyou; Zhou Xian; Cortes Jorge
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Blood 2005;105(6):2281-6.
2004: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Luthra Rajyalakshmi; Giles Francis; Verstovsek Srdan; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Jones Dan; Talpaz Moshe
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Bueso-Ramos Carlos E; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Medeiros L Jeffrey; Kantarjian Hagop
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Cancer 2004;101(2):332-6.
2004: Esmaeli B; Diba R; Ahmadi M A; Saadati H G; Faustina M M; Shepler T R; Talpaz M; Fraunfelder R; Rios M B; Kantarjian H
Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).
Eye (London, England) 2004;18(7):760-2.
2004: Cortes Jorge E; O'Brien Susan M; Giles Francis; Alvarez Ricardo H; Talpaz Moshe; Kantarjian Hagop M
Investigational strategies in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):619-39, ix.
2004: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Garcia-Manero Guillermo; Rios Mary B; Talpaz Moshe; Cortes Jorge
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
Cancer 2004;100(12):2592-7.
2004: Cortes Jorge; O'Brien Susan; Quintas Alfonso; Giles Francis; Shan Jianquin; Rios Mary Beth; Talpaz Moshe; Kantarjian Hagop
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cancer 2004;100(11):2396-402.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Bharti Alok C; Shishodia Shishir; Reuben James M; Weber Donna; Alexanian Raymond; Raj-Vadhan Saroj; Estrov Zeev; Talpaz Moshe; Aggarwal Bharat B
Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.
Blood 2004;103(8):3175-84.
2004: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Giles Francis; Rios Mary Beth; Shan Jianqin; Letvak Laurie; Thomas Deborah; Faderl Stefan; Ferrajoli Alessandra; Cortes Jorge
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: El-Zimaity Maha M T; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Thomas Deborah; Ferrajoli Alessandra; Hayes Kimberly; Nebiyou Bekele B; Zhou Xian; Rios Mary B; Glassman Armand B; Cortes Jorge E
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
British journal of haematology 2004;125(2):187-95.
2004: Peng Bin; Hayes Michael; Resta Debra; Racine-Poon Amy; Druker Brian J; Talpaz Moshe; Sawyers Charles L; Rosamilia Marianne; Ford John; Lloyd Peter; Capdeville Renaud
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):935-42.
2004: Donato Nicholas J; Wu Ji Y; Stapley Jonathan; Lin Hui; Arlinghaus Ralph; Aggarwal Bharat B; Shishodia Shishir; Albitar Maher; Hayes Kimberly; Kantarjian Hagop; Talpaz Moshe;
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Cancer research 2004;64(2):672-7.
2004: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Shan Jianqin; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Keating Michael; Talpaz Moshe
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2004: Sneed Thomas B; Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Rios Mary Beth; Bekele B Nebiyou; Zhou Xian; Resta Debra; Wierda William; Faderl Stefan; Giles Francis; Cortes Jorge E
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2004: Yan Yan; Phan Leuyen; Yang Fan; Talpaz Moshe; Yang Yu; Xiong Zeyu; Ng Bernard; Timchenko Nikolai A; Wu Catherine J; Ritz Jerome; Wang Hong; Yang Xiao-Feng
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(1):651-60.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Keating Michael; Talpaz Moshe
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Tsao Anne S; Kantarjian Hagop; Cortes Jorge; O'Brien Susan; Talpaz Moshe
Imatinib mesylate causes hypopigmentation in the skin.
Cancer 2003;98(11):2483-7.
2003: Wu Hillary H; Talpaz Moshe; Champlin Richard E; Pilat Susan R; Kurzrock Razelle
Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Cancer 2003;98(11):2410-9.
2003: Kurzrock Razelle; Kantarjian Hagop M; Cortes Jorge E; Singhania Neil; Thomas Deborah A; Wilson Edward F; Wright John J; Freireich Emil J; Talpaz Moshe; Sebti Saïd M
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Blood 2003;102(13):4527-34.
2003: Giles Francis J; Feldman Eric J; Roboz Gail J; Larson Richard A; Mamus Steven W; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; Talpaz Moshe; Beran Miloslav; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Medina Jorge; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Rios Mary Beth; Hayes Kimberly; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Cancer 2003;98(9):1905-11.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorges; Shan Jianqin; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Rios Mary Beth; Talpaz Moshe
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Laurent Eunice; Mitchell David L; Estrov Zeev; Lowery Megan; Tucker Susan L; Talpaz Moshe; Kurzrock Razelle
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3722-30.
2003: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Beth Rios Mary; Shan Jianquin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge; Rios Mary Beth; Shan Jianqin; Thomas Deborah; Andreeff Michael; Kornblau Steven; Faderl Stefan; Garcia-Manero Guillermo; White Kevin; Mallard Susie; Freireich Emil; Kantarjian Hagop M
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Issa Jean-Pierre; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Andreeff Michael; Keating Michael; Talpaz Moshe
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Garcia-Manero Guillermo; Faderl Stefan; O'Brien Susan; Cortes Jorge; Talpaz Moshe; Kantarjian Hagop M
Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Cancer 2003;98(3):437-57.
2003: Polek Tara C; Talpaz Moshe; Darnay Bryant G; Spivak-Kroizman Taly
TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor.
The Journal of biological chemistry 2003;278(34):32317-23.
2003: Estrov Zeev; Shishodia Shishir; Faderl Stefan; Harris David; Van Quin; Kantarjian Hagop M; Talpaz Moshe; Aggarwal Bharat B
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
Blood 2003;102(3):987-95.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Thomas Deborah; Kornblau Steven; Shan Jianquin; Beth Rios Mary; Keating Michael; Freireich Emil; Talpaz Moshe
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Cancer 2003;98(1):81-5.
2003: Faderl Stefan; Harris David; Van Quin; Kantarjian Hagop M; Talpaz Moshe; Estrov Zeev
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Blood 2003;102(2):630-7.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Freireich Emil J; Talpaz Moshe; Kantarjian Hagop
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Garcia-Manero Guillermo; Talpaz Moshe; Giles Francis J; Cortes Jorge; Faderl Stefan; O'Brien Susan; Thomas Deborah; Verstovsek Srdan; Beth Rios Mary; Shan Jianquin; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop M
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Albitar Maher; Rios Mary Beth; Talpaz Moshe; Garcia-Manero Guillermo; Faderl Stefan; Letvak Laurie; Salvado August; Kantarjian Hagop
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Kurzrock Razelle; Kantarjian Hagop M; Druker Brian J; Talpaz Moshe
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Annals of internal medicine 2003;138(10):819-30.
2003: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; White Kevin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Kornblau Steven; Cortes Jorge
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Cortes Jorge E; Talpaz Moshe; Giles Francis; O'Brien Susan; Rios Mary Beth; Shan Jianqin; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah A; Wierda William; Ferrajoli Allessandra; Jeha Sima; Kantarjian Hagop M
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Mattiuzzi Gloria N; Cortes Jorge E; Talpaz Moshe; Reuben James; Rios Mary Beth; Shan Jianjin; Kontoyiannis Dimitrios; Giles Francis J; Raad Issam; Verstovsek Srdan; Ferrajoli Alessandra; Kantarjian Hagop M
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Cortes Jorge; Albitar Maher; Thomas Deborah; Giles Francis; Kurzrock Razelle; Thibault Alain; Rackoff Wayne; Koller Charles; O'Brien Susan; Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2003: Ravandi Farhad; Talpaz Moshe; Estrov Zeev
Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):535-50.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Shan Jianqin; Giles Francis J; Rios Mary Beth; Faderl Stefan H; Wierda William G; Ferrajoli Alessandra; Verstovsek Srdan; Keating Michael J; Freireich Emil J; Talpaz Moshe
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Kantarjian Hagop M; Talpaz Moshe; Cortes Jorge; O'Brien Susan; Faderl Stefan; Thomas Deborah; Giles Francis; Rios Mary Beth; Shan Jianqin; Arlinghaus Ralph
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):160-6.
2003: Donato Nicholas J; Wu Ji Yuan; Stapley Jonathan; Gallick Gary; Lin Hui; Arlinghaus Ralph; Talpaz Moshe
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Blood 2003;101(2):690-8.
2003: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Jeha Sima; Rios Mary Beth; Letvak Laurie; Bochinski Kathy; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2003: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Guo J Q; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus R B
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(12):2447-53.
2002: Tsao Anne S; Kantarijian Hagop; Talpaz Moshe
STI-571 in chronic myelogenous leukaemia.
British journal of haematology 2002;119(1):15-24.
2002: Giles Francis J; Kantarjian Hagop M; Bekele B Nebiyou; Cortes Jorge E; Faderl Stephan; Thomas Deborah A; Manshouri Taghi; Rogers Anna; Keating Michael J; Talpaz Moshe; O'Brien Susan; Albitar Maher
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Talpaz Moshe
Treatment of CML: thoughts after ASCO 2002.
MedGenMed : Medscape general medicine 2002;4(4):11.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Giralt Sergio A; Rios Mary Beth; Shan Jianqin; Giles Francis J; Thomas Deborah A; Faderl Stefan; De Lima Marcos; Garcia-Manero Guillermo; Champlin Richard; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Esmaeli Bita; Prieto Victor G; Butler Charles E; Kim Stella K; Ahmadi M Amir; Kantarjian Hagop M; Talpaz Moshe
Severe periorbital edema secondary to STI571 (Gleevec).
Cancer 2002;95(4):881-7.
2002: Cheng Keding; Kurzrock Razelle; Qiu Xiangguo; Estrov Zeev; Ku Stella; Dulski Kim M; Wang Jean Y J; Talpaz Moshe
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.
Cancer 2002;95(2):440-50.
2002: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Smith Terry L; Giles Francis J; Faderl Stefan; Thomas Deborah A; Garcia-Manero Guillermo; Issa Jean-Pierre J; Andreeff Michael; Kornblau Steven M; Koller Charles; Beran Milosav; Keating Michael; Rios Mary Beth; Shan Jenny; Resta Debra; Capdeville Renaud; Hayes Kimberly; Albitar Maher; Freireich Emil J; Cortes Jorge E
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Smith Terry L; Rios Mary Beth; Shan Jianqin; Yang Ying; Giles Francis J; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Jeha Sima; Wierda William; Issa Jean-Pierre J; Kornblau Steven M; Keating Michael; Resta Debra; Capdeville Renaud; Talpaz Moshe
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Atallah Ehab; Talpaz Moshe; O'brien Susan; Rios Mary Beth; Guo Jie Qiang; Arlinghaus Ralph; Fernandes-Reese Sofia; Kantarjian Hagop
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Cancer 2002;94(11):2996-9.
2002: Lee W I; Kantarjian H; Glassman A; Talpaz M; Lee M S
Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):781-8.
2002: Verstovsek Srdan; Lin Hui; Kantarjian Hagop; Saglio Giuseppe; De Micheli Daniela; Pane Fabrizio; Garcia-Manero Guillermo; Intrieri Mariano; Rotoli Bruno; Salvatore Francesco; Guo Jie Q; Talpaz Moshe; Specchia Giorgina; Pizzolo Gianni; Liberati Anna Marina; Cortes Jorge; Quackenbush Robert C; Arlinghaus Ralph B
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.
Cancer 2002;94(9):2416-25.
2002: Kantarjian Hagop M; Cortes Jorge; O'Brien Susan; Giles Francis J; Albitar Maher; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Resta Debra; Talpaz Moshe
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Sawyers Charles L; Hochhaus Andreas; Feldman Eric; Goldman John M; Miller Carole B; Ottmann Oliver G; Schiffer Charles A; Talpaz Moshe; Guilhot Francois; Deininger Michael W N; Fischer Thomas; O'Brien Steve G; Stone Richard M; Gambacorti-Passerini Carlo B; Russell Nigel H; Reiffers Jose J; Shea Thomas C; Chapuis Bernard; Coutre Steven; Tura Sante; Morra Enrica; Larson Richard A; Saven Alan; Peschel Christian; Gratwohl Alois; Mandelli Franco; Ben-Am Monique; Gathmann Insa; Capdeville Renaud; Paquette Ronald L; Druker Brian J
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blood 2002;99(10):3530-9.
2002: Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop M
Current therapy of chronic myelogenous leukemia.
Internal medicine (Tokyo, Japan) 2002;41(4):254-64.
2002: O'Brien Susan; Talpaz Moshe; Cortes Jorge; Shan Jianqin; Giles Francis J; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Mallard Susie; Beth Mary; Koller Charles; Kornblau Steve; Andreeff Michael; Murgo Anthony; Keating Michael; Kantarjian Hagop M
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; O'Brien Susan; Faderl Stefan; Talpaz Moshe; Cortes Jorge; Albitar Maher
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Cancer 2002;94(5):1517-21.
2002: Talpaz Moshe; Silver Richard T; Druker Brian J; Goldman John M; Gambacorti-Passerini Carlo; Guilhot Francois; Schiffer Charles A; Fischer Thomas; Deininger Michael W N; Lennard Anne L; Hochhaus Andreas; Ottmann Oliver G; Gratwohl Alois; Baccarani Michele; Stone Richard; Tura Sante; Mahon Francois-Xavier; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; Kantarjian Hagop M; Sawyers Charles L
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Kantarjian Hagop; Sawyers Charles; Hochhaus Andreas; Guilhot Francois; Schiffer Charles; Gambacorti-Passerini Carlo; Niederwieser Dietger; Resta Debra; Capdeville Renaud; Zoellner Ulrike; Talpaz Moshe; Druker Brian; Goldman John; O'Brien Stephen G; Russell Nigel; Fischer Thomas; Ottmann Oliver; Cony-Makhoul Pascale; Facon Thierry; Stone Richard; Miller Carole; Tallman Martin; Brown Randy; Schuster Michael; Loughran Thomas; Gratwohl Alois; Mandelli Franco; Saglio Giuseppe; Lazzarino Mario; Russo Domenico; Baccarani Michele; Morra Enrica;
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
The New England journal of medicine 2002;346(9):645-52.
2002: Angelo Laura S; Talpaz Moshe; Kurzrock Razelle
Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
Cancer research 2002;62(3):932-40.
2002: Ravandi Farhad; Talpaz Moshe; Kantarjian Hagop; Estrov Zeev
Cellular signalling pathways: new targets in leukaemia therapy.
British journal of haematology 2002;116(1):57-77.
2002: Estrov Zeev; Huh Yang O; Ginsberg Cheryl F; Harris David; Van Quin; Mirza Nadeem Q; Talpaz Moshe; Korbling Martin
Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors.
Journal of clinical apheresis 2002;17(1):7-16.
2001: Kantarjian H M; Shan J; Smith T; Talpaz M; Kozuch P; Rios M B; Cortes J; Giles F J; O'Brien S
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Kurzrock R; Cortes J; Thomas D A; Jeha S; Pilat S; Talpaz M
Pilot study of low-dose interleukin-11 in patients with bone marrow failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4165-72.
2001: Kantarjian H M; Talpaz M
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Seminars in oncology 2001;28(5 Suppl 17):9-18.
2001: Kantarjian H M; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien S M
Homoharringtonine: history, current research, and future direction.
Cancer 2001;92(6):1591-605.
2001: Kardinal C; Konkol B; Lin H; Eulitz M; Schmidt E K; Estrov Z; Talpaz M; Arlinghaus R B; Feller S M
Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes.
Blood 2001;98(6):1773-81.
2001: Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles F J; Faderl S; Kantarjian H M
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Kalidas M; Kantarjian H; Talpaz M
Chronic myelogenous leukemia.
JAMA : the journal of the American Medical Association 2001;286(8):895-8.
2001: Talpaz M
Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition.
Seminars in hematology 2001;38(3 Suppl 8):22-7.
2001: Kurzrock R; Kantarjian H; Talpaz M
Chronic myelogenous leukemia in chronic phase.
Current treatment options in oncology 2001;2(3):245-52.
2001: Ravandi F; Kantarjian H M; Talpaz M; O'Brien S; Faderl S; Giles F J; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios M B; Albitar M
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Kurzrock R; Bueso-Ramos C E; Kantarjian H; Freireich E; Tucker S L; Siciliano M; Pilat S; Talpaz M
BCR rearrangement-negative chronic myelogenous leukemia revisited.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2915-26.
2001: Ravandi F; Hayes K; Cortes J; Albitar M; Glassman A; Talpaz M; Kantarjian H M
Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia.
Cancer 2001;91(9):1704-8.
2001: Donato N J; Wu J Y; Zhang L; Kantarjian H; Talpaz M
Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
Blood 2001;97(9):2846-53.
2001: Gisslinger H; Kurzrock R; Gisslinger B; Jiang S; Li S; Virgolini I; Woloszczuk W; Andreeff M; Talpaz M
Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor.
Blood 2001;97(9):2791-7.
2001: Giles F J; Kantarjian H; O'Brien S; Rios M B; Cortes J; Beran M; Koller C; Keating M; Talpaz M
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Leukemia & lymphoma 2001;41(3-4):309-19.
2001: Druker B J; Sawyers C L; Kantarjian H; Resta D J; Reese S F; Ford J M; Capdeville R; Talpaz M
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The New England journal of medicine 2001;344(14):1038-42.
2001: Druker B J; Talpaz M; Resta D J; Peng B; Buchdunger E; Ford J M; Lydon N B; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers C L
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
The New England journal of medicine 2001;344(14):1031-7.
2001: Laurent E; Talpaz M; Kantarjian H; Kurzrock R
The BCR gene and philadelphia chromosome-positive leukemogenesis.
Cancer research 2001;61(6):2343-55.
2001: Gordon M S; Margolin K; Talpaz M; Sledge G W; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):843-50.
2001: Wang Y; Liu J; Wu Y; Luo W; Lin S H; Lin H; Hawk N; Sun T; Guo J Q; Estrov Z; Talpaz M; Champlin R; Arlinghaus R B
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Cancer research 2001;61(1):138-44.
2001: Shimoni A; Gajewski J A; Donato M; Martin T; O'Brien S; Talpaz M; Cohen A; Korbling M; Champlin R; Giralt S
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2001;7(10):568-75.
2000: Faderl S; Kantarjian H M; Talpaz M; Estrov Z
Clinical significance of minimal residual disease in leukemia.
International journal of oncology 2000;17(6):1277-87.
2000: Tannir N M; Talpaz M; Ghazal H; Proothi S; Kantarjian H M
Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.
Leukemia & lymphoma 2000;39(5-6):647-50.
2000: Berman E; Clift R A; Copelan E A; Emanuel P D; Erba H P; Glenn M J; Greenberg P L; Jones R J; O'Brien S; Saba H I; Schilder R; Snyder D S; Soiffer R J; Tallman M S; Wetzler M; Ravandi-Kashani F; Kantarjian H; Talpaz M;
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
Oncology (Williston Park, N.Y.) 2000;14(11A):229-40.
2000: Laurent E; Talpaz M; Wetzler M; Kurzrock R
Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(11):1892-7.
2000: Faderl S; Kantarjian H M; Talpaz M; O'Brien S
New treatment approaches for chronic myelogenous leukemia.
Seminars in oncology 2000;27(5):578-86.
2000: Kantarjian H M; Giles F J; O'Brien S; Giralt S; Talpaz M
Therapeutic choices in younger patients with chronic myelogenous leukemia.
Cancer 2000;89(8):1647-58.
2000: Kantarjian H M; Talpaz M; Smith T L; Cortes J; Giles F J; Rios M B; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: Kozuch P; Talpaz M; Faderl S; O'Brien S; Freireich E J; Kantarjian H
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?
Cancer 2000;89(7):1482-9.
2000: Talpaz M; Qiu X; Cheng K; Cortes J E; Kantarjian H; Kurzrock R
Autoantibodies to Abl and Bcr proteins.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(9):1661-6.
2000: Donato N J; Talpaz M
Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):2965-6.
2000: Kardinal C; Konkol B; Schulz A; Posern G; Lin H; Adermann K; Eulitz M; Estrov Z; Talpaz M; Arlinghaus R B; Feller S M
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(11):1529-38.
2000: Reuben J M; Lee B N; Johnson H; Fritsche H; Kantarjian H M; Talpaz M
Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1671-7.
2000: Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles F J; Pierce S; Albitar M
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Cancer 2000;88(3):570-6.
2000: Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith T L; Rios M B; Kantarjian H
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):147-52.
1999: Kantarjian H M; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios M B; Croce C M; Albitar M
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Faderl S; Thall P F; Kantarjian H M; Talpaz M; Harris D; Van Q; Beran M; Kornblau S M; Pierce S; Estrov Z
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4041-7.
1999: Ravandi F; Estrov Z; Kurzrock R; Breitmeyer J B; Maschek B J; Talpaz M
A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3990-8.
1999: Sacchi S; Kantarjian H M; O'Brien S; Cortes J; Rios M B; Giles F J; Beran M; Koller C A; Keating M J; Talpaz M
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Ravandi F; Cortes J; Albitar M; Arlinghaus R; Qiang Guo J; Talpaz M; Kantarjian H M
Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.
British journal of haematology 1999;107(3):581-6.
1999: Sacchi S; Kantarjian H M; Freireich E J; O'Brien S; Cortes J; Rios M B; Kornblau S; Giles F J; Koller C; Gajewski J; Talpaz M
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Giles F J; Keating A R; Kurzrock R; Talpaz M
A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(11):1253-5.
1999: Estrov Z; Manna S K; Harris D; Van Q; Estey E H; Kantarjian H M; Talpaz M; Aggarwal B B
Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells.
Blood 1999;94(8):2844-53.
1999: Ravandi-Kashani F; Cortes J; Cohen P; Talpaz M; O'Brien S; Markowitz A; Kantarjian H
Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Leukemia & lymphoma 1999;35(1-2):109-18.
1999: Silver R T; Woolf S H; Hehlmann R; Appelbaum F R; Anderson J; Bennett C; Goldman J M; Guilhot F; Kantarjian H M; Lichtin A E; Talpaz M; Tura S
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
Blood 1999;94(5):1517-36.
1999: Giles F J; Kantarjian H M; Cortes J; Thomas D A; Talpaz M; Manshouri T; Albitar M
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Cancer 1999;86(5):805-13.
1999: Seong D; Kantarjian H M; Albitar M; Arlinghaus R; Xu J; Talpaz M; Rios M B; Guo J Q; O'Brien S; Siciliano M
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):955-9.
1999: Faderl S; Talpaz M; Estrov Z; Kantarjian H M
Chronic myelogenous leukemia: biology and therapy.
Annals of internal medicine 1999;131(3):207-19.
1999: Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian H M
The biology of chronic myeloid leukemia.
The New England journal of medicine 1999;341(3):164-72.
1999: Beaupre D M; Talpaz M; Marini F C; Cristiano R J; Roth J A; Estrov Z; Albitar M; Freedman M H; Kurzrock R
Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.
Cancer research 1999;59(12):2971-80.
1999: Ravandi-Kashani F; Cortes J; Talpaz M; Kantarjian H M
Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?
Cancer 1999;85(12):2583-8.
1999: O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios M B; Talpaz M
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
Blood 1999;93(12):4149-53.
1999: Faderl S; Talpaz M; Kantarjian H M; Estrov Z
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood 1999;93(9):2755-9.
1999: Issa J P; Kantarjian H; Mohan A; O'Brien S; Cortes J; Pierce S; Talpaz M
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
Blood 1999;93(6):2075-80.
1999: Faderl S; Kantarjian H M; Talpaz M
Chronic myelogenous leukemia: update on biology and treatment.
Oncology (Williston Park, N.Y.) 1999;13(2):169-80; discussion 181, 184.
1999: Kantarjian H M; O'Brien S; Smith T L; Rios M B; Cortes J; Beran M; Koller C; Giles F J; Andreeff M; Kornblau S; Giralt S; Keating M J; Talpaz M
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1998: Rodriguez J; Cortes J; Smith T; O'Brien S; Rios M B; Talpaz M; Kantarjian H
Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3782-7.
1998: Estrov Z; Thall P F; Talpaz M; Estey E H; Kantarjian H M; Andreeff M; Harris D; Van Q; Walterscheid M; Kornblau S M
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia.
Blood 1998;92(9):3090-7.
1998: Krainick U; Kantarjian H; Broussard S; Talpaz M
Local cutaneous necrotizing lesions associated with interferon injections.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(10):823-7.
1998: Cortes J; Talpaz M; O'Brien S; Rios M B; Majlis A; Keating M; Freireich E J; Kantarjian H
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3279-85.
1998: Kantarjian H M; Talpaz M
Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia.
Blood 1998;92(8):2984-7.
1998: Wright-Browne V; Schnee A M; Jenkins M A; Thall P F; Aggarwal B B; Talpaz M; Estrov Z
Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence.
Leukemia & lymphoma 1998;30(5-6):583-9.
1998: Fayad L; Cabanillas F; Talpaz M; McLaughlin P; Kurzrock R
High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.
Leukemia & lymphoma 1998;30(5-6):563-71.
1998: Ferrajoli A; Talpaz M; Kurzrock R; Harris D; Van Q; Estey E H; Estrov Z
Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
Leukemia & lymphoma 1998;30(3-4):279-92.
1998: Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus R B; Lydon N B; Kantarjian H
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1661-72.
1998: Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson L E; O'Brien S
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2321-31.
1998: Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(6):860-4.
1998: Faderl S; Kantarjian H M; Talpaz M; Estrov Z
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia.
Blood 1998;91(11):3995-4019.
1998: Randhawa G S; Cui H; Barletta J A; Strichman-Almashanu L Z; Talpaz M; Kantarjian H; Deisseroth A B; Champlin R C; Feinberg A P
Loss of imprinting in disease progression in chronic myelogenous leukemia.
Blood 1998;91(9):3144-7.
1998: Estrov Z; Talpaz M; Ku S; Harris D; Van Q; Beran M; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia.
Leukemia research 1998;22(4):341-53.
1998: Seong D; Thall P; Kantarjian H M; Talpaz M; Swantkowski J; Xu J; Shen Y; Glassman A; Ramagli L; Siciliano M J
Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):861-7.
1998: Cortes J; Fayad L; Kantarjian H; O'Brien S; Lee M S; Talpaz M
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(4):455-62.
1998: Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1526-31.
1998: Kurzrock R; Estrov Z; Ku S; Leonard M; Talpaz M
Interleukin-1 increases expression of the LYT-10 (NFkappaB2) proto-oncogene/transcription factor in renal cell carcinoma lines.
The Journal of laboratory and clinical medicine 1998;131(3):261-8.
1998: Sacchi S; Kantarjian H M; Smith T L; O'Brien S; Pierce S; Kornblau S; Beran M; Keating M J; Talpaz M
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):882-9.
1998: Kantarjian H M; Giles F J; O'Brien S M; Talpaz M
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
Hematology/oncology clinics of North America 1998;12(1):31-80.
1998: Kurzrock R; Talpaz M; Beran M; Harris D; Estrov Z
DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(2):242-6.
1998: Oka T; Sastry K J; Nehete P; Schapiro S J; Guo J Q; Talpaz M; Arlinghaus R B
Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(2):155-63.
1998: Wilhelm M; Bueso-Ramos C; O'Brien S; Pierce S; Keating M; Talpaz M; Kantarjian H M
Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(1):65-70.
1997: Kantarjian H M; Talpaz M; O'Brien S; Kurzrock R; Gutterman J; Keating M J; McCredie K B; Freireich E J
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2723-33.
1997: O'Brien S; Kantarjian H; Beran M; Koller C; Talpaz M; Lerner S; Keating M J
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1631-5.
1997: Kantarjian H M; O'Brien S M; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios M B; de Vos D; Talpaz M
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1617-20.
1997: Sacchi S; Kantarjian H M; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating M J; Talpaz M
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1610-6.
1997: Peleg S; Qiu H; Reddy S; Harris D; Van Q; Estey E H; Talpaz M; Estrov Z
1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.
The Journal of clinical investigation 1997;100(7):1716-24.
1997: Bseiso A W; Kantarjian H M; Guo J Q; Cortes J; Talpaz M; Koller C; AlBitar M; Keating M; Arlinghaus R
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(9):1583-7.
1997: Preti H A; Cabanillas F; Talpaz M; Tucker S L; Seymour J F; Kurzrock R
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma.
Annals of internal medicine 1997;127(3):186-94.
1997: Rodriguez-Monge E J; Cortes J E; O'Brien S; Talpaz M; Kantarjian H M
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
Cancer 1997;80(3):396-400.
1997: Cortes J; Kantarjian H; O'Brien S; Beran M; Estey E; Keating M; Talpaz M
A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):929-32.
1997: Talpaz M; Kantarjian H M; O'Brien S; Kurzrock R
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):291-305.
1997: Cortes J; Kantarjian H M; Giralt S; Talpaz M
Natural history and staging of chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):277-90.
1997: Wetzler M; Kurzrock R; Estrov Z; Barone S; Estey E; Talpaz M
Suppressed formation of bone marrow adherent layers derived from acute myeloid leukemia patients after in vitro exposure to interleukin-4.
Leukemia research 1997;21(6):519-27.
1997: Cortes J; Kantarjian H; Talpaz M; O'Brien S; Beran M; Koller C; Keating M
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(6):788-91.
1997: Fayad L; Kantarjian H; O'Brien S; Seong D; Albitar M; Keating M; Talpaz M
Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(5):767-71.
1997: Kurzrock R; Strom S S; Estey E; O'Brien S; Keating M J; Jiang H; Adams T; Talpaz M
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1803-10.
1997: Wright-Browne V; McClain K L; Talpaz M; Ordonez N; Estrov Z
Physiology and pathophysiology of dendritic cells.
Human pathology 1997;28(5):563-79.
1997: Kantarjian H M; O'Brien S M; Estey E; Giralt S; Beran M; Rios M B; Keating M; de Vos D; Talpaz M
Decitabine studies in chronic and acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 1():S35-6.
1997: Gisslinger H; Kurzrock R; Wetzler M; Tucker S; Kantarjian H; Robertson B; Talpaz M
Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences.
Leukemia & lymphoma 1997;25(1-2):121-33.
1997: Estrov Z; Talpaz M
Role of interleukin-1 beta converting enzyme (ICE) in acute myelogenous leukemia cell proliferation and programmed cell death.
Leukemia & lymphoma 1997;24(5-6):379-91.
1997: Seymour J F; Talpaz M; Hagemeister F B; Cabanillas F; Kurzrock R
Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
The American journal of medicine 1997;102(1):21-8.
1997: Seymour J F; Talpaz M; Kurzrock R
Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(1):42-7.
1997: Sacchi S; Cortes J; Kantarjian H; Talpaz M
Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
Hematopathology and molecular hematology 1997;11(1):41-7.
1996: O'Brien S; Kantarjian H; Talpaz M
Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha.
Leukemia & lymphoma 1996;23(3-4):247-52.
1996: Guo J Q; Lian J; Glassman A; Talpaz M; Kantarjian H; Deisseroth A B; Arlinghaus R B
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
American journal of clinical pathology 1996;106(4):442-8.
1996: Kattan M W; Inoue Y; Giles F J; Talpaz M; Ozer H; Guilhot F; Zuffa E; Huber S L; Beck J R
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
Annals of internal medicine 1996;125(7):541-8.
1996: Estrov Z; Talpaz M; Ku S; Harris D; LaPushin R; Koller C A; Hirsh-Ginsberg C; Huh Y; Yee G; Kurzrock R
Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(9):1534-43.
1996: Seong D; Bruner J M; Lee K H; Mirza N; Kwon B D; Lee J H; Lee Y Y; Ro J; Talpaz M; Champlin R; Deisseroth A B
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(2):402-3.
1996: Khouri I F; Kantarjian H M; Talpaz M; Giralt S; Rios M O; Hester J P; Champlin R E; Deisseroth A B
Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.
Bone marrow transplantation 1996;17(5):775-9.
1996: Sarris A H; Talpaz M; Deisseroth A B; Estrov Z
Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(5):757-65.
1996: Cortes J E; Talpaz M; Kantarjian H
Chronic myelogenous leukemia: a review.
The American journal of medicine 1996;100(5):555-70.
1996: Kellokumpu-Lehtinen P; Talpaz M; Harris D; Van Q; Kurzrock R; Estrov Z
Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways.
International journal of cancer. Journal international du cancer 1996;66(4):515-9.
1996: Cortes J; Kantarjian H; O'Brien S; Robertson L E; Pierce S; Talpaz M
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
The American journal of medicine 1996;100(4):452-5.
1996: Kantarjian H M; O'Brien S; Anderlini P; Talpaz M
Treatment of myelogenous leukemia: current status and investigational options.
Blood 1996;87(8):3069-81.
1996: Estrov Z; Talpaz M
Role of interleukin-1 beta converting enzyme (ICE) in leukemia.
Cytokines and molecular therapy 1996;2(1):1-11.
1996: Nicolson N L; Talpaz M; Nicolson G L
Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia.
Gene 1996;169(2):173-8.
1996: Eton O; Talpaz M; Lee K H; Rothberg J M; Brell J M; Benjamin R S
Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
Cancer 1996;77(5):893-9.
1996: Estrov Z; Talpaz M; Zipf T F; Kantarjian H M; Ku S; Ouspenskaia M V; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Journal of cellular physiology 1996;166(3):618-30.
1996: Majlis A; Smith T L; Talpaz M; O'Brien S; Rios M B; Kantarjian H M
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):196-203.
1995: Estrov Z; Black R A; Sleath P R; Harris D; Van Q; LaPushin R; Estey E H; Talpaz M
Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation.
Blood 1995;86(12):4594-602.
1995: Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Blood 1995;86(11):4337-43.
1995: O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson L E; Hester J; Rios M B; Andreeff M; Talpaz M
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
Blood 1995;86(9):3322-6.
1995: Estrov Z; Samal B; Lapushin R; Kellokumpu-Lehtinen P; Sahin A A; Kurzrock R; Talpaz M; Aggarwal B B
Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(10):905-13.
1995: Wetzler M; Kantarjian H; Kurzrock R; Talpaz M
Interferon-alpha therapy for chronic myelogenous leukemia.
The American journal of medicine 1995;99(4):402-11.
1995: Kurzrock R; Wetzler M; Estrov Z; Talpaz M
Interleukin-1 and its inhibitors: a biologic and therapeutic model for the role of growth regulatory factors in leukemias.
Cytokines and molecular therapy 1995;1(3):177-84.
1995: Verschraegen C F; Kantarjian H M; Hirsch-Ginsberg C; Lee M S; O'Brien S; Rios M B; Stass S A; Keating M; Talpaz M
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations.
Cancer 1995;76(6):992-7.
1995: Sacchi S; Kantarjian H; O'Brien S; Cohen P R; Pierce S; Talpaz M
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2401-7.
1995: Seong D C; Kantarjian H M; Ro J Y; Talpaz M; Xu J; Robinson J R; Deisseroth A B; Champlin R E; Siciliano M J
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.
Blood 1995;86(6):2343-9.
1995: Estrov Z; Talpaz M; Estey E H; Strassmann G
Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
Experimental hematology 1995;23(10):1080-7.
1995: Wetzler M; Kurzrock R; Goodacre A M; McLaughlin P; Ku S; Talpaz M
Transformation of chronic lymphocytic leukemia to lymphoma of true histiocytic type.
Cancer 1995;76(4):609-17.
1995: Giralt S; Kantarjian H; Talpaz M
Treatment of chronic myelogenous leukemia.
Seminars in oncology 1995;22(4):396-404.
1995: Estrov Z; Kurzrock R; Talpaz M
Cytokines and their antagonists in myeloid disorders.
Seminars in hematology 1995;32(3):220-31.
1995: Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan K W; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
Cytokines and molecular therapy 1995;1(2):115-22.
1995: Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
Blood 1995;85(11):3257-63.
1995: Nicolson N L; Talpaz M; Nicolson G L
Interferon-alpha directly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complexes: correlation with IFN-alpha treatment outcome in patients with chronic myelogenous leukemia.
Gene 1995;159(1):105-11.
1995: Estrov Z; Talpaz M; Mavligit G; Pazdur R; Harris D; Greenberg S M; Kurzrock R
Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis.
The American journal of medicine 1995;98(6):551-8.
1995: Pavol M A; Meyers C A; Rexer J L; Valentine A D; Mattis P J; Talpaz M
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia.
Neurology 1995;45(5):947-50.
1995: Kantarjian H M; Talpaz M
Interferon-alpha therapy in chronic myelogenous leukemia: questions related to the German randomized trial.
Blood 1995;85(10):2998-9, 3000-2.
1995: Verschraegen C F; Talpaz M; Hirsch-Ginsberg C F; Pherwani R; Rios M B; Stass S A; Kantarjian H M
Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia.
Blood 1995;85(10):2705-10.
1995: Talpaz M; Kantarjian H
Low-dose interferon-alpha in chronic myeloid leukemia.
Annals of internal medicine 1995;122(9):728-9.
1995: Cortes J E; Talpaz M; Cabanillas F; Seymour J F; Kurzrock R
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Blood 1995;85(9):2516-20.
1995: Wetzler M; Talpaz M; Yee G; Stass S A; Van Etten R A; Andreeff M; Goodacre A M; Kleine H D; Mahadevia R K; Kurzrock R
Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(8):3488-92.
1995: Giralt S; Kantarjian H; Talpaz M
The natural history of chronic myelogenous leukemia in the interferon era.
Seminars in hematology 1995;32(2):152-8.
1995: Seymour J F; Talpaz M; Cabanillas F; Wetzler M; Kurzrock R
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):575-82.
1995: Kantarjian H M; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios M B; Smith T L; Calvert L; Deisseroth A B
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):553-9.
1995: Kantarjian H M; Smith T L; O'Brien S; Beran M; Pierce S; Talpaz M
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Annals of internal medicine 1995;122(4):254-61.
1995: Wetzler M; Kurzrock R; Estrov Z; Estey E; Talpaz M
Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia.
Leukemia research 1995;19(1):23-34.
1995: Kurzrock R; Ku S; Talpaz M
Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines.
Cancer 1995;75(2):584-90.
1995: Cortes J E; Talpaz M; Beran M; O'Brien S M; Rios M B; Stass S; Kantarjian H M
Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results.
Cancer 1995;75(2):464-70.
1995: Estrov Z; Kurzrock R; Talpaz M
Interleukin-1 and its inhibitors: implications for disease biology and therapy.
Cancer treatment and research 1995;80():51-82.
1995: Valentine A D; Meyers C A; Talpaz M
Treatment of neurotoxic side effects of interferon-alpha with naltrexone.
Cancer investigation 1995;13(6):561-6.
1994: Kantarjian H M; Talpaz M
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Seminars in oncology 1994;21(6 Suppl 14):8-13.
1994: Talpaz M
Use of interferon in the treatment of chronic myelogenous leukemia.
Seminars in oncology 1994;21(6 Suppl 14):3-7.
1994: Wetzler M; Kurzrock R; Estrov Z; Kantarjian H; Gisslinger H; Underbrink M P; Talpaz M
Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.
Blood 1994;84(9):3142-7.
1994: Ferrajoli A; Talpaz M; Ordonez N G; Stanley E R; Hirsch-Ginsberg C; Zipf T F; Wetzler M; Kurzrock R; Estrov Z
Interleukin 4 alters human bone marrow stroma and modulates its interaction with hematopoietic progenitors.
Stem cells (Dayton, Ohio) 1994;12(6):638-49.
1994: Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
The Journal of clinical investigation 1994;94(4):1383-9.
1994: Kantarjian H M; Talpaz M; Andersson B; Khouri I; Giralt S; Rios M B; Champlin R; Hester J; Deisseroth A B
High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
Bone marrow transplantation 1994;14(1):57-61.
1994: Guo J Q; Lian J Y; Xian Y M; Lee M S; Deisseroth A B; Stass S A; Champlin R E; Talpaz M; Wang J Y; Arlinghaus R B
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
Blood 1994;83(12):3629-37.
1994: Ferrajoli A; Talpaz M; Zipf T F; Hirsch-Ginsberg C; Estey E; Wolpe S D; Estrov Z
Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(5):798-805.
1994: Wetzler M; Estrov Z; Talpaz M; Kim K J; Alphonso M; Srinivasan R; Kurzrock R
Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
Cancer research 1994;54(7):1837-42.
1994: Kantarjian H M; Deisseroth A; Talpaz M
Chronic myelogenous leukemia--update and future directions.
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 1994;Suppl():118-24.
1994: Kantarjian H; Talpaz M; Estey E; Ku S; Kurzrock R
What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?
The American journal of medicine 1994;96(2):133-8.
1993: Ferrajoli A; Zipf T F; Talpaz M; Felix E A; Estrov Z
Growth factors controlling interleukin-4 action on hematopoietic progenitors.
Annals of hematology 1993;67(6):277-84.
1993: Wetzler M; Talpaz M; Van Etten R A; Hirsh-Ginsberg C; Beran M; Kurzrock R
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
The Journal of clinical investigation 1993;92(4):1925-39.
1993: Kantarjian H M; Talpaz M
Therapy of chronic myelogenous leukemia.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():8-9.
1993: Deisseroth A B; Kantarjian H; Talpaz M; Champlin R; Reading C; Hanania E G; Fu S; Randhawa G S; Cha Y; Fang X
Molecular approaches to the diagnosis and treatment of cancer.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():129-30.
1993: Wetzler M; Estrov Z; Talpaz M; Markowitz A; Gutterman J U; Kurzrock R
Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma.
Journal of internal medicine 1993;234(4):417-20.
1993: Estrov Z; Kurzrock R; Talpaz M
Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia.
Leukemia & lymphoma 1993;10(6):407-18.
1993: Griesshammer M; Hehlmann R; Hochhaus A; Talpaz M; Tura S; Stryckmans P; Allan N C; Tanzer J; Kolb H J; Heimpel H
Interferon in chronic myeloid leukemia. A workshop report.
Annals of hematology 1993;67(2):101-6.
1993: Kantarjian H M; Deisseroth A; Kurzrock R; Estrov Z; Talpaz M
Chronic myelogenous leukemia: a concise update.
Blood 1993;82(3):691-703.
1993: Kurzrock R; Estey E; Talpaz M
All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1489-95.
1993: Estrov Z; Talpaz M; Kantarjian H M; Zipf T F; McClain K L; Kurzrock R
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
Cancer research 1993;53(14):3289-93.
1993: Giralt S A; Kantarjian H M; Talpaz M; Rios M B; Del Giglio A; Andersson B S; Przepiorka D; Deisseroth A B; Champlin R E
Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1055-61.
1993: Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Cancer research 1993;53(9):2118-22.
1993: Ferrajoli A; Talpaz M; Kurzrock R; Estrov Z
Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesis.
Stem cells (Dayton, Ohio) 1993;11(2):112-9.
1993: Estrov Z; Kurzrock R; Pocsik E; Pathak S; Kantarjian H M; Zipf T F; Harris D; Talpaz M; Aggarwal B B
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
The Journal of experimental medicine 1993;177(3):763-74.
1993: Deisseroth A B; Kantarjian H; Talpaz M; Champlin R; Reading C; Andersson B; Claxton D
Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine.
Human gene therapy 1993;4(1):71-85.
1993: Estrov Z; Markowitz A B; Kurzrock R; Wetzler M; Kantarjian H M; Ferrajoli A; Gutterman J U; Talpaz M
Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1993;7(2):214-20.
1993: Derderian P M; Kantarjian H M; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
The American journal of medicine 1993;94(1):69-74.
1993: Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman J U; Talpaz M
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Experimental hematology 1993;21(1):80-5.
1993: Wetzler M; Talpaz M; Estrov Z; Kurzrock R
CML: mechanisms of disease initiation and progression.
Leukemia & lymphoma 1993;11 Suppl 1():47-50.
1993: Kantarjian H M; Talpaz M
Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
Leukemia & lymphoma 1993;11 Suppl 1():169-74.
1992: Lee M; Khouri I; Champlin R; Kantarjian H; Talpaz M; Trujillo J; Freireich E; Deisseroth A; Stass S
Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.
British journal of haematology 1992;82(4):708-14.
1992: Seong D C; Gottlieb K; Suh S P; Sims S; Talpaz M; Kantarjian H; Deisseroth A
Identification of a complex formed between nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells of CML but not normal individuals.
Journal of interferon research 1992;12(5):323-7.
1992: Estrov Z; Talpaz M; Wetzler M; Kurzrock R
The modulatory hematopoietic activities of leukemia inhibitory factor.
Leukemia & lymphoma 1992;8(1-2):1-7.
1992: Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman P S; Ku S; Gutterman J U; Talpaz M
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(8):754-60.
1992: Estrov Z; Park C H; Reading C L; Estey E H; Talpaz M; Kurzrock R; Deisseroth A B; Gutterman J U
The effect of granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors.
Experimental hematology 1992;20(7):886-90.
1992: Kurzrock R; Talpaz M; Gutterman J U
Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
The American journal of medicine 1992;93(1):41-8.
1992: Estrov Z; Estey E H; Andreeff M; Talpaz M; Kurzrock R; Reading C L; Deisseroth A B; Gutterman J U
Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
Experimental hematology 1992;20(5):558-64.
1992: Kantarjian H M; Keating M J; Estey E H; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: Lee M S; Kantarjian H; Talpaz M; Freireich E J; Deisseroth A; Trujillo J M; Stass S A
Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.
Blood 1992;79(8):1920-3.
1992: Wetzler M; Talpaz M; Kellagher M J; Gutterman J U; Kurzrock R
Myelokathexis: normalization of neutrophil counts and morphology by GM-CSF.
JAMA : the journal of the American Medical Association 1992;267(16):2179-80.
1992: Estrov Z; Kurzrock R; Estey E; Wetzler M; Ferrajoli A; Harris D; Blake M; Gutterman J U; Talpaz M
Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors.
Blood 1992;79(8):1938-45.
1992: Kantarjian H M; Talpaz M; Kontoyiannis D; Gutterman J; Keating M J; Estey E H; O'Brien S; Rios M B; Beran M; Deisseroth A
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):398-405.
1992: Talpaz M; Chernajovsky Y; Troutman-Worden K; Wetzler M; Kantarjian H; Gutterman J U; Kurzrock R
Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients.
Cancer research 1992;52(5):1087-90.
1992: Claxton D; Deisseroth A; Talpaz M; Reading C; Kantarjian H; Trujillo J; Stass S; Gooch G; Spitzer G
Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
Blood 1992;79(4):997-1002.
1992: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
Cancer 1992;69(2):410-2.
1992: Yuan T; Zhou Y Q; Herst C V; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
Progress in clinical and biological research 1992;377():227-30.
1991: Estrov Z; Kurzrock R; Talpaz M; Blake M; Gutterman J U
Granulocyte-macrophage colony-stimulating factor and interleukin-3 in combination: a potent and consistent myelodysplastic syndrome bone marrow stimulant in vitro.
Annals of hematology 1991;63(6):297-301.
1991: Upadhyaya G; Guba S C; Sih S A; Feinberg A P; Talpaz M; Kantarjian H M; Deisseroth A B; Emerson S G
Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells.
The Journal of clinical investigation 1991;88(6):2131-6.
1991: Kurzrock R; Talpaz M; Estey E; O'Brien S; Estrov Z; Gutterman J U
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(11):985-90.
1991: Kantarjian H M; Talpaz M; Dhingra K; Estey E; Keating M J; Ku S; Trujillo J; Huh Y; Stass S; Kurzrock R
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood 1991;78(9):2411-8.
1991: Wetzler M; Kurzrock R; Lowe D G; Kantarjian H; Gutterman J U; Talpaz M
Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.
Blood 1991;78(9):2400-6.
1991: Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman J U
A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Cancer 1991;68(10):2125-30.
1991: Itoh K; Balch C M; Murray J L; Parkinson D R; Markowitz A B; Talpaz M; Lee K; Zukiwski A A; Ross M I; Legha S S
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies.
In vivo (Athens, Greece) 1991;5(6):647-53.
1991: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Interferon alpha in the therapy of CML.
British journal of haematology 1991;79 Suppl 1():38-41.
1991: Kurzrock R; Talpaz M
The molecular pathology of chronic myelogenous leukaemia.
British journal of haematology 1991;79 Suppl 1():34-7.
1991: Schilling P J; Kurzrock R; Kantarjian H; Gutterman J U; Talpaz M
Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
Cancer 1991;68(7):1536-7.
1991: Kurzrock R; Talpaz M; Gutterman J U
Hairy cell leukaemia: review of treatment.
British journal of haematology 1991;79 Suppl 1():17-20.
1991: Kurzrock R; Talpaz M; Gutterman J U
Treatment of cyclic neutropenia with very low doses of GM-CSF.
The American journal of medicine 1991;91(3):317-8.
1991: Kantarjian H M; Talpaz M; Keating M J; Estey E H; O'Brien S; Beran M; McCredie K B; Gutterman J; Freireich E J
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: Estrov Z; Kurzrock R; Wetzler M; Kantarjian H; Blake M; Harris D; Gutterman J U; Talpaz M
Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.
Blood 1991;78(6):1476-84.
1991: Kurzrock R; Estrov Z; Wetzler M; Gutterman J U; Talpaz M
LIF: not just a leukemia inhibitory factor.
Endocrine reviews 1991;12(3):208-17.
1991: Kurzrock R; Talpaz M; Estrov Z; Rosenblum M G; Gutterman J U
Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1241-50.
1991: Seong D; Sims S; Johnson E; Lyding J; Lopez A; Garovoy M; Talpaz M; Kantarjian H; Lopez-Berestein G; Reading C
Activation of class I HLA expression by TNF-alpha and gamma-interferon is mediated through protein kinase C-dependent pathway in CML cell lines.
British journal of haematology 1991;78(3):359-67.
1991: Kurzrock R; Talpaz M; Gomez J A; Estey E H; O'Brien S; Hirsch-Ginsberg C; Koller C; Freireich E J; Gutterman J U
Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
British journal of haematology 1991;78(3):352-8.
1991: Wetzler M; Talpaz M; Lowe D G; Baiocchi G; Gutterman J U; Kurzrock R
Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta.
Experimental hematology 1991;19(5):347-51.
1991: Kantarjian H M; Talpaz M; LeMaistre C F; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth A B
Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
Cancer 1991;67(12):2959-65.
1991: O'Brien S; Witt R; Talpaz M; Kantarjian H
Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
Cancer 1991;67(7):1946-9.
1991: Talpaz M; Kantarjian H; Kurzrock R; Trujillo J M; Gutterman J U
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Annals of internal medicine 1991;114(7):532-8.
1991: Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman J U; Kurzrock R
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(3):191-5.
1991: Estey E H; Kurzrock R; Talpaz M; McCredie K B; O'Brien S; Kantarjian H M; Keating M J; Deisseroth A B; Gutterman J U
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1991: Estrov Z; Talpaz M; Chou T C; Kurzrock R; Blake M; Gutterman J U
Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(2):101-7.
1991: Dhingra K; Talpaz M; Dhingra H M; Ajani J A; Rothberg J M; Gutterman J U
A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum.
Investigational new drugs 1991;9(1):37-9.
1991: Baiocchi G; Kavanagh J J; Talpaz M; Wharton J T; Gutterman J U; Kurzrock R
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies.
Cancer 1991;67(4):990-6.
1991: Dhingra K; Talpaz M; Riggs M G; Eastman P S; Zipf T; Ku S; Kurzrock R
Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias.
Blood 1991;77(2):238-42.
1991: Keating M J; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs C C; Freireich E J; McCredie K B
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):44-9.
1991: Itoh K; Hayakawa K; Salmeron M A; Legha S S; Murray J L; Talpaz M; Balch C M; Parkinson D R; Lee K; Zukiwski A A
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy.
Cancer immunology, immunotherapy : CII 1991;33(4):238-46.
1991: Kurzrock R; Estrov Z; Talpaz M; Gutterman J U
Cytokines in tumor therapy. Interleukin-3.
American journal of clinical oncology 1991;14 Suppl 1():S45-50.
1990: Wedrychowski A; Seong D; Paslidis N; Johnson E; Howard O M; Sims S; Talpaz M; Kantarjian H; Hester J; Turpin J
Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells.
The Journal of biological chemistry 1990;265(35):21433-40.
1990: Seong D C; Sims S; Johnson E; Howard O M; Reiter B; Hester J; Talpaz M; Kantarjian H; Deisseroth A
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes.
The Journal of clinical investigation 1990;86(5):1664-70.
1990: Wetzler M; Talpaz M; Kleinerman E S; King A; Huh Y O; Gutterman J U; Kurzrock R
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia.
The American journal of medicine 1990;89(5):663-72.
1990: Howard O M; Talpaz M; Kantarjian H; Seong D; Wedrychowski A; Paslidis N; Hester J; Cork A; Turpin J; Lopez-Berestein G
Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
Blood 1990;76(6):1117-30.
1990: Hirsch-Ginsberg C; LeMaistre A C; Kantarjian H; Talpaz M; Cork A; Freireich E J; Trujillo J M; Lee M S; Stass S A
RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia.
Blood 1990;76(6):1214-9.
1990: Wetzler M; Kurzrock R; Taylor K; Spitzer G; Kantarjian H; Baiocchi G; Ku S; Gutterman J U; Talpaz M
Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma.
Cancer research 1990;50(18):5801-5.
1990: Gutterman J; Vadhan-Raj S; Logothetis C; Anaissle E; Estey E; Talpaz M; Kurzrock R
Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.
Seminars in hematology 1990;27(3 Suppl 3):15-24.
1990: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Update on therapeutic options for chronic myelogenous leukemia.
Seminars in hematology 1990;27(3 Suppl 4):31-6.
1990: Estey E H; Dixon D; Kantarjian H M; Keating M J; McCredie K; Bodey G P; Kurzrock R; Talpaz M; Freireich E J; Deisseroth A B
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Kantarjian H M; Kurzrock R; Talpaz M
Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia.
Hematology/oncology clinics of North America 1990;4(2):389-404.
1990: Kurzrock R; Kantarjian H M; Shtalrid M; Gutterman J U; Talpaz M
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Blood 1990;75(2):445-52.
1990: Kantarjian H M; Keating M J; Smith T L; Talpaz M; McCredie K B
Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia.
The American journal of medicine 1990;88(1):1-8.
1990: Mashal R; Shtalrid M; Talpaz M; Kantarjian H; Smith L; Beran M; Cork A; Trujillo J; Gutterman J; Deisseroth A
Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia.
Blood 1990;75(1):180-9.
1990: Seong D; Sims S S; Johnson E; Swan F; Lyding J; Lopez A; Talpaz M; Kantarjian H; Emerson S; Lopez-Berestein G
Regulation of gene expression by tumor necrosis factor-alpha and interferon-gamma in chronic myelogenous leukemia.
Transactions of the Association of American Physicians 1990;103():236-41.
1990: Claxton D; Kantarjian H; Kurzrock R; Trujillo J M; Gutterman J U; Talpaz M
Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia.
Acta haematologica 1990;83(3):149-51.
1989: Lee K H; Talpaz M; Rothberg J M; Murray J L; Papadopoulos N; Plager C; Benjamin R; Levitt D; Gutterman J
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1726-32.
1989: Kurzrock R; Feinberg B; Talpaz M; Saks S; Gutterman J U
Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
Journal of interferon research 1989;9(4):435-44.
1989: Keating M J; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich E J; McCredie K B
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Blood 1989;74(1):19-25.
1989: Lee M S; LeMaistre A; Kantarjian H M; Talpaz M; Freireich E J; Trujillo J M; Stass S A
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.
Blood 1989;73(8):2165-70.
1989: Parkinson D R; Talpaz M; Lee K H; Legha S; Markowitz A B; Itoh K; Balch C M; Murray J L; Zukiwski A A; Benjamin R S
Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.
Cancer treatment reviews 1989;16 Suppl A():39-48.
1989: Taylor K M; Shetta M; Talpaz M; Kantarjian H M; Hardikar S; Chinault A C; McCredie K B; Spitzer G
Myeloproliferative disorders: usefulness of X-linked probes in diagnosis.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(6):419-22.
1989: Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman J U
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
The American journal of medicine 1989;86(5):554-8.
1989: Lee K H; Gutterman J U; Ali M K; Talpaz M
Cardiac arrhythmia in a CML patient treated with interferons.
Texas medicine 1989;85(4):36-8.
1989: LeMaistre A; Lee M S; Talpaz M; Kantarjian H M; Freireich E J; Deisseroth A B; Trujillo J M; Stass S A
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia.
Blood 1989;73(4):889-91.
1989: Kurzrock R; Talpaz M; Gutterman U
Biological molecules in the treatment of hematological disorders.
Sangre 1989;34(1):53-8.
1989: Romero P; Beran M; Shtalrid M; Andersson B; Talpaz M; Blick M
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
Oncogene 1989;4(1):93-8.
1989: Talpaz M; Kantarjian H; Kurzrock R; Gutterman J U
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
Bone marrow transplantation 1989;4 Suppl 1():63.
1989: Talpaz M; Kurzrock R; Kantarjian H; Gutterman J
Therapy of chronic myelogenous leukaemia with interferons.
Cancer surveys 1989;8(4):793-8.
1989: Kurzrock R; Gutterman J U; Kantarjian H; Talpaz M
Therapy of chronic myelogenous leukemia with interferon.
Cancer investigation 1989;7(1):83-91.
1988: Cohen P R; Talpaz M; Kurzrock R
Malignancy-associated Sweet's syndrome: review of the world literature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(12):1887-97.
1988: Shtalrid M; Talpaz M; Blick M; Romero P; Kantarjian H; Taylor K; Trujillo J; Schachner J; Gutterman J U; Kurzrock R
Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(10):1569-75.
1988: Blennerhassett G T; Furth M E; Anderson A; Burns J P; Chaganti R S; Blick M; Talpaz M; Dev V G; Chan L C; Wiedemann L M
Clinical evaluation of a DNA probe assay for the Philadelphia (Ph1) translocation in chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(10):648-57.
1988: Kurzrock R; Gutterman J U; Talpaz M
The molecular genetics of Philadelphia chromosome-positive leukemias.
The New England journal of medicine 1988;319(15):990-8.
1988: Lee M S; Chang K S; Freireich E J; Kantarjian H M; Talpaz M; Trujillo J M; Stass S A
Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.
Blood 1988;72(3):893-7.
1988: Feinberg B; Kurzrock R; Talpaz M; Blick M; Saks S; Gutterman J U
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(8):1328-34.
1988: Shtalrid M; Talpaz M; Kurzrock R; Kantarjian H; Trujillo J; Gutterman J; Yoffe G; Blick M
Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia.
Blood 1988;72(2):485-90.
1988: Talpaz M
The activity of alpha interferons in chronic myelogenous leukemia.
The American journal of the medical sciences 1988;296(2):95-7.
1988: Kantarjian H M; Walters R S; Keating M J; Talpaz M; Andersson B; Beran M; McCredie K B; Freireich E J
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
Cancer 1988;62(4):672-6.
1988: Kantarjian H M; Dixon D; Keating M J; Talpaz M; Walters R S; McCredie K B; Freireich E J
Characteristics of accelerated disease in chronic myelogenous leukemia.
Cancer 1988;61(7):1441-6.
1988: Talpaz M
Activity of alpha-interferons in chronic myelogenous leukaemia.
British journal of clinical practice. Supplement 1988;62():13-5.
1988: Kantarjian H M; Talpaz M
Definition of the accelerated phase of chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(1):180-2.
1988: Talpaz M
Clinical studies of alpha-interferons in chronic myelogenous leukemia.
Cancer treatment reviews 1988;15 Suppl A():49-53.
1988: Talpaz M; Kantarjian H M; Kurzrock R; Gutterman J
Therapy of chronic myelogenous leukemia: chemotherapy and interferons.
Seminars in hematology 1988;25(1):62-73.
1988: O'Brien S; Kantarjian H; Shtalrid M; Blick M; Beran M; Talpaz M
Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Hematologic pathology 1988;2(1):25-9.
1988: Lee J; Talpaz M; Walters R; Gutterman J U; Blick M
Aberrant expression of the K-ras proto-oncogene in B-cell malignancies.
Hematologic pathology 1988;2(4):229-37.
1988: Kantarjian H M; Talpaz M; Gutterman J U
Chronic myelogenous leukemia--past, present, and future.
Hematologic pathology 1988;2(2):91-120.
1988: Talpaz M; Kurzrock R; Kantarjian H M; Gutterman J U
Recent advances in the therapy of chronic myelogenous leukemia.
Important advances in oncology 1988;():297-321.
1988: Keating M J; Kantarjian H; Talpaz M; Redman J; McCredie K B
Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Nouvelle revue française d'hématologie 1988;30(5-6):461-6.
1987: Kurzrock R; Shtalrid M; Talpaz M; Kloetzer W S; Gutterman J U
Expression of c-abl in Philadelphia-positive acute myelogenous leukemia.
Blood 1987;70(5):1584-8.
1987: Kantarjian H M; Keating M J; McCredie K B; Walters R; Talpaz M; Smith T L; Freireich E J
Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia.
Southern medical journal 1987;80(10):1228-32.
1987: Walters R S; Kantarjian H M; Keating M J; Talpaz M; Childs C C; McCredie K B; Freireich E J
Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron.
Cancer 1987;60(8):1708-12.
1987: Kurzrock R; Talpaz M; Kantarjian H; Walters R; Saks S; Trujillo J M; Gutterman J U
Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.
Blood 1987;70(4):943-7.
1987: Kurzrock R; Shtalrid M; Gutterman J U; Koller C A; Walters R; Trujillo J M; Talpaz M
Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia.
British journal of haematology 1987;67(1):55-9.
1987: Kantarjian H M; Keating M J; Talpaz M; Walters R S; Smith T L; Cork A; McCredie K B; Freireich E J
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
The American journal of medicine 1987;83(3):445-54.
1987: Kantarjian H M; Talpaz M; Gutterman J
Biologic therapy of chronic myelogenous leukemia.
Oncology (Williston Park, N.Y.) 1987;1(7):35-40, 48-9, 52.
1987: Blick M; Romero P; Talpaz M; Kurzrock R; Shtalrid M; Andersson B; Trujillo J; Beran M; Gutterman J
Molecular characteristics of chronic myelogenous leukemia in blast crisis.
Cancer genetics and cytogenetics 1987;27(2):349-56.
1987: Yoffe G; Chinault A C; Talpaz M; Blick M B; Kantarjian H M; Taylor K; Spitzer G
Clonal nature of Philadelphia chromosome-positive and -negative chronic myelogenous leukemia by DNA hybridization analyses.
Experimental hematology 1987;15(7):725-8.
1987: Kurzrock R; Kloetzer W S; Talpaz M; Blick M; Walters R; Arlinghaus R B; Gutterman J U
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia.
Blood 1987;70(1):233-6.
1987: Talpaz M; Kantarjian H M; McCredie K B; Keating M J; Trujillo J; Gutterman J
Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
Blood 1987;69(5):1280-8.
1987: Dekmezian R; Kantarjian H M; Keating M J; Talpaz M; McCredie K B; Freireich E J
The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia.
Cancer 1987;59(10):1739-43.
1987: Talpaz M; Rosenblum M; Kurzrock R; Reuben J; Kantarjian H; Gutterman J
Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study.
American journal of hematology 1987;24(4):341-50.
1987: Lee J S; Dixon D O; Kantarjian H M; Keating M J; Talpaz M
Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients.
Blood 1987;69(3):929-36.
1987: Yoffe G; Blick M; Kantarjian H; Spitzer G; Gutterman J; Talpaz M
Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia.
Blood 1987;69(3):961-3.
1987: Maxwell S A; Kurzrock R; Parsons S J; Talpaz M; Gallick G E; Kloetzer W S; Arlinghaus R B; Kouttab N M; Keating M J; Gutterman J U
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Cancer research 1987;47(6):1731-9.
1987: Talpaz M; Kantarjian H; McCredie K; Trujillo J; Keating M; Gutterman J U
Therapy of chronic myelogenous leukemia.
Cancer 1987;59(3 Suppl):664-7.
1987: Terjanian T; Kantarjian H; Keating M; Talpaz M; McCredie K; Freireich E J
Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease.
Cancer 1987;59(2):297-300.
1987: O'Brien S; Kantarjian H M; Talpaz M; Cork A; Trujillo J; Beran M
The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations.
Hematologic pathology 1987;1(3):167-72.
1987: McCredie K B; Talpaz M; Kantarjian H; Rosenblum M; Keating M; Gutterman J
Biologic agents for the management of hematological disorders: chronic myeloid leukemia.
Haematology and blood transfusion 1987;31():120-2.
1987: Kantarjian H M; Talpaz M; Kurzrock R; Keating M J; McCredie K B; Gutterman J; Freireich E J
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():70-4.
1986: Kantarjian H M; Keating M J; Walters R S; McCredie K B; Smith T L; Talpaz M; Beran M; Cork A; Trujillo J M; Freireich E J
Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia.
Cancer 1986;58(9):2023-30.
1986: Kurzrock R; Blick M B; Talpaz M; Velasquez W S; Trujillo J M; Kouttab N M; Kloetzer W S; Arlinghaus R B; Gutterman J U
Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia.
Annals of internal medicine 1986;105(5):673-9.
1986: Talpaz M; McCredie K; Kantarjian H; Trujillo J; Keating M; Gutterman J
Chronic myelogenous leukaemia: haematological remissions with alpha interferon.
British journal of haematology 1986;64(1):87-95.
1986: Rosenblum M G; Maxwell B L; Talpaz M; Kelleher P J; McCredie K B; Gutterman J U
In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha-interferon: correlation with receptor binding and induction of 2',5'-oligoadenylate synthetase.
Cancer research 1986;46(9):4848-52.
1986: Talpaz M; Spitzer G; Hittelman W; Kantarjian H; Gutterman J
Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients.
Experimental hematology 1986;14(7):668-71.
1986: Kurzrock R; Quesada J R; Talpaz M; Hersh E M; Reuben J M; Sherwin S A; Gutterman J U
Phase I study of multiple dose intramuscularly administered recombinant gamma interferon.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(7):1101-9.
1986: Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
European journal of cancer & clinical oncology 1986;22(6):685-9.
1986: Patt Y Z; Mavligit G M; Reuben J; Mansell P W; Li S; Newell G; Talpaz M; Hersh E M
Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon.
Journal of biological response modifiers 1986;5(3):263-9.
1986: Talpaz M; Kantarjian H M; McCredie K; Trujillo J M; Keating M J; Gutterman J U
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
The New England journal of medicine 1986;314(17):1065-9.
1986: Calabretta B; Venturelli D; Kaczmarek L; Narni F; Talpaz M; Anderson B; Beran M; Baserga R
Altered expression of G1-specific genes in human malignant myeloid cells.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(5):1495-8.
1986: Romero P; Blick M; Talpaz M; Murphy E; Hester J; Gutterman J
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
Blood 1986;67(3):839-41.
1986: Quesada J R; Talpaz M; Rios A; Kurzrock R; Gutterman J U
Clinical toxicity of interferons in cancer patients: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(2):234-43.
1985: Kantarjian H M; Smith T L; McCredie K B; Keating M J; Walters R S; Talpaz M; Hester J P; Bligham G; Gehan E; Freireich E J
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Blood 1985;66(6):1326-35.
1985: McLaughlin P; Talpaz M; Quesada J R; Saleem A; Barlogie B; Gutterman J U
Immune thrombocytopenia following alpha-interferon therapy in patients with cancer.
JAMA : the journal of the American Medical Association 1985;254(10):1353-4.
1985: Talpaz M; Trujillo J M; Hittelman W N; Keating M J; Gutterman J U
Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon.
British journal of haematology 1985;60(4):619-24.
1985: Maxwell B L; Talpaz M; Gutterman J U
Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapy.
International journal of cancer. Journal international du cancer 1985;36(1):23-8.
1985: Kurzrock R; Rosenblum M G; Sherwin S A; Rios A; Talpaz M; Quesada J R; Gutterman J U
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.
Cancer research 1985;45(6):2866-72.
1985: Mars W M; Florine D L; Talpaz M; Saunders G F
Preferentially expressed genes in chronic myelogenous leukemia.
Blood 1985;65(5):1218-25.
1985: Kloetzer W; Kurzrock R; Smith L; Talpaz M; Spiller M; Gutterman J; Arlinghaus R
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity.
Virology 1985;140(2):230-8.
1984: Talpaz M; Spitzer G
Low natural killer cell activity in the bone marrow of healthy donors with normal killer cell activity in the peripheral blood.
Experimental hematology 1984;12(8):629-32.
1984: Mavligit G M; Talpaz M
Cimetidine for herpes zoster.
The New England journal of medicine 1984;310(5):318-9.
1984: Mavligit G M; Talpaz M; Hsia F T; Wong W; Lichtiger B; Mansell P W; Mumford D M
Chronic immune stimulation by sperm alloantigens. Support for the hypothesis that spermatozoa induce immune dysregulation in homosexual males.
JAMA : the journal of the American Medical Association 1984;251(2):237-41.
1983: Schattner A; Shani A; Talpaz M; Bentwich Z
Rheumatoid factors in the sera of patient with gastrointestinal carcinoma.
Cancer 1983;52(11):2156-61.
1983: Talpaz M; Mavligit G; Keating M; Walters R S; Gutterman J U
Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia.
Annals of internal medicine 1983;99(6):789-92.
1983: Talpaz M; Mavligit G M
Characterization of human effector and suppressor T cells by their activity in mixed lymphocyte reaction and by monoclonal antibody phenotyping.
Journal of clinical & laboratory immunology 1983;12(4):217-20.
1983: Talpaz M; McCredie K B; Mavligit G M; Gutterman J U
Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.
Blood 1983;62(3):689-92.
1983: Talpaz M; Kim E; Guardini M; Sun Y; Wong W; Kasi L; Mavligit G
Objective evaluation of local xenogeneic graft-versus-host reaction by computerized radioisotope imaging (CRI).
Journal of immunological methods 1983;61(2):133-9.
1983: Sun Y; Hersh E M; Talpaz M; Lee S L; Wong W; Loo T L; Mavligit G M
Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs.
Cancer 1983;52(1):70-3.
1983: Talpaz M; Wong W; Medina J; Goepfert H; Mavligit G
The immune restorative effect of Isoprinosine administration on the local graft-versus-host reaction of cancer patients.
Clinical immunology and immunopathology 1983;28(1):96-100.
1983: Lopez-Berestein G; Reuben J; Hersh E M; Kilbourn R; Hester J P; Bielski M; Talpaz M; Mavligit G M
Comparative functional analysis of lymphocytes and monocytes from plateletapheresis.
Transfusion 1983;23(3):201-6.
1982: Talpaz M; Medina J E; Patt Y Z; Goepfert H; Guillamondegui O M; Wong W; Mavligit G M
The immune restorative effect of cimetidine administration in vivo on the local graft-versus-host reaction of cancer patients.
Clinical immunology and immunopathology 1982;24(2):155-60.
1982: Yancey R S; Talpaz M
Vindesine-associated angina and ECG changes.
Cancer treatment reports 1982;66(3):587-9.
1982: Talpaz M; Bielski M; Hersh E M
Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission.
Cancer immunology, immunotherapy : CII 1982;14(2):96-8.
1980: Talpaz M
[Immunosuppressive drugs in systemic lupus erythematosus and rheumatoid arthritis]
Harefuah 1980;98(10):468-71.
1979: Shani A; Talpaz M; Chemke J; Rappaport S; Stein J A
Absence of chromosomal changes in fetus after paternal chemotherapy.
Lancet 1979;2(8143):637.
1979: Schattner A; Talpaz M; Eliraz A
[Thrombosis of the subclavian and innominate veins three years before the appearance of lung cancer]
Harefuah 1979;96(12):652-4.
1979: Talpaz M; Bentwich Z
[Early ambulation after acute myocardial infarction]
Harefuah 1979;96(3):160-1.
1979: Bentwich Z; Talpaz M
[Duration of hospitalization and convalescence of patients with acute myocardial infarction]
Harefuah 1979;96(3):133-4.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Moshe Talpaz

Research Profile (preview)

Disorders

Chemicals & Drugs

Anatomy

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Moshe Talpaz (preview)

All Publications